← Back to Search

Behavioural Intervention

Geriatric Care Optimization for Blood Cancers

N/A
Waitlist Available
Led By Sarah Wall, MD
Research Sponsored by Ohio State University Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplantation. This includes acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelofibrosis, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, and aplastic anemia. Disease specific eligibility for allo-HCT to be determined by treating physician
Age >= 60 years
Must not have
No possibility of proceeding to allogeneic hematopoietic cell transplant within the next 6 months as determined by treating physician
Scheduled admission for allogeneic hematopoietic cell transplant within 30 days of enrollment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 6 months before transplant, up to 12 months after transplant
Awards & highlights

Summary

This trial studies if a plan tailored to the individual can improve survival & quality of life for patients over 60 w/ hematologic malignancy or bone marrow failure syndrome receiving an allogeneic hematopoietic cell transplant.

Who is the study for?
This trial is for people over 60 with blood cancers or bone marrow failure who are eligible for a stem cell transplant. They must be able to understand English and commit to the study's full duration. Those with dementia, no transplant planned within 6 months, or a scheduled transplant within 30 days can't join.
What is being tested?
The OTIS Study tests a geriatric optimization plan (GO!) aimed at improving survival in older adults through personalized lifestyle changes like diet, sleep, activity adjustments, medication reviews, and specialist referrals before their stem cell transplants.
What are the potential side effects?
Since this trial focuses on health promotion rather than drugs or invasive procedures, side effects may include discomfort from lifestyle changes or stress from additional medical appointments and assessments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am eligible for a stem cell transplant due to my blood-related cancer or condition.
Select...
I am 60 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not eligible for a bone marrow transplant from a donor within the next 6 months.
Select...
I am scheduled for a stem cell transplant from a donor within the next 30 days.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 6 months before transplant, up to 12 months after transplant
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months before transplant, up to 12 months after transplant for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in 6-Minute Walk Test distance
Secondary study objectives
Adherence to prescribed geriatric optimization plan (GO!) prescription
Change in Short Physical Performance Battery score
Change in cognitive and mental health
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Supportive care (GO!)Experimental Treatment4 Interventions
Patients undergo personalized GO! plan consisting of study visits over 50 minutes at baseline and 6 months after first visit or at the time of hospital admission for bone marrow transplant and over 25 minutes at 3 and 12 months after transplant. Patients complete questionnaires once a month for up to 6 months and wear an accelerometer for up to 6 months.

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
334 Previous Clinical Trials
291,578 Total Patients Enrolled
Sarah Wall, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center

Media Library

Geriatric Optimization Plan (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05972577 — N/A
Acute Lymphoblastic Leukemia Research Study Groups: Supportive care (GO!)
Acute Lymphoblastic Leukemia Clinical Trial 2023: Geriatric Optimization Plan Highlights & Side Effects. Trial Name: NCT05972577 — N/A
Geriatric Optimization Plan (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05972577 — N/A
~7 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top